FDA says Aldara "approvable" for superficial basal cell carcinoma Tx

Article

Source: www.pharmalive.com 3M has received an ?approvable? letter from the FDA in response to its supplemental new drug application on Aldara (imiquimod cream), 5 percent, for treatment of superficial basal cell carcinoma, a common form of non-melanoma skin cancer.

Related Videos
Related Content

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023

Holistic Aesthetics Center to Host First Annual Symposium in Middletown, New York

September 24th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Weekly Roundup: September 18-22

September 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Colloidal Oatmeal Effective in Improving Atopic Dermatitis in Black Children

September 22nd 2023

Combination Treatments in HS Require Further Review

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.